Mosunetuzumab (Lunsumio) for Follicular Lymphoma
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1671f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Bispecific, Antineoplastic Agents.
Abstract (Originalsprache)
Mosunetuzumab-axgb (Lunsumio – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for treatment of relapsed or refractory follicular lymphoma in adults who received ≥2 lines of systemic therapy. It is the first T-cell-engaging bispecific antibody to be approved in the US for this indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Mosunetuzumab (Lunsumio) for Follicular Lymphoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1671f
Vancouver
Mosunetuzumab (Lunsumio) for Follicular Lymphoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1671f
BibTeX
@article{euvimed2023,
title = {Mosunetuzumab (Lunsumio) for Follicular Lymphoma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1671f}
}
EUVIMED